48 episodes

Highlights and interviews from the 2016 AACR conference.

AACR 2016 ecancer

    • Medicine

Highlights and interviews from the 2016 AACR conference.

    • video
    Galectins in tumour immunity

    Galectins in tumour immunity

    Dr Gabriel Rabinovich meets with ecancertv at AACR 2016 to discuss galectins.

    Galectin 1, secreted by tumour cells, kills T cells and promotes non-immunogenic tumourous dendritic cell growth.

    Beyond immune suppression, galectins are also linked to angiogenesis, which further promotes the persistence of the tumour microenvironment.

    Dr Rabinovich reports on the current trials of galectin targeted therapy, and his upcoming research.

    • 3 min
    • video
    Innovations in assessing patient outcomes

    Innovations in assessing patient outcomes

    Dr Heather Jim speaks with ecancertv at AACR 2016 about novel technologies in evaluating and integrating patient responses to therapies.

    She describes how patient involvement has altered data acquisition and trial design, using technologies commonly available to patients at home with less cost and wider engagement than existing techniques.

    With consideration of patients symptoms and response to therapies, Dr Jim hopes that novel technologies and even current wearable technologies could enable a more responsive, personalised care programme at low cost and significant benefit.

    • 6 min
    • video
    Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types

    Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types

    Dr Alexander Drilon speaks with ecancertv at AACR 2016 on results from phase I trials of entrectinib, a new treatment for TRK fusions with additional effects on Ros1 and Alk.

    He reports it as a safe, low toxicity treatment, with significant improvement on patient quality of life.

    Dr Drilion advocates further testing of these fusions in patients, with entrectinib now approaching phase II trials.

    • 7 min
    • video
    Technologies for personalised cancer immunotherapies

    Technologies for personalised cancer immunotherapies

    Prof James Heath speaks with ecancertv at AACR 2016 about neoantigens, a highly-personalised course of immunotherapy.

    He explains the process of identifying and isolating mutant markers from a patients genome, to then process these novel targets as a T cell receptors.

    He also discusses the current costs of therapy, considering the development of technology in recent years and looking forward to a future of faster, cheaper, patient-specific treatments.

    • 7 min
    • video
    Targeting T regs in tumours

    Targeting T regs in tumours

    Dr Dario Vignali speaks with ecancertv at AACR 2016 about his work with regulatory T cells, an essential part of innate immunity but also modulated within the tumour microenvironment.

    Looking beyond current checkpoint inhibitory research, he describes T regs as a promising avenue for further investigation, such as ongoing trials of mogamulizumab, a CCR4 antibody.

    Considering wide interest in immunotherapy, especially as combination therapies, Dr Vignali describes the potential impact of understanding T regs on numerous aspects of medicine.

    • 6 min
    • video
    Repopulation of cancer stem cells in therapeutic resistance

    Repopulation of cancer stem cells in therapeutic resistance

    Dr Keith Chan speaks with ecancertv at AACR 2016 about ongoing research to target cancer stem cells.

    Cancer stem cells are steadfastly resistant to traditional therapies, and can repopulate tumour cells in the same way as a healthy body heals a wound.

    This repopulation, Dr Chan reports, can come during the pauses between a patient's therapies, and is infact stimulated by the cell death caused by chemotherapy.

    Dr Chan discusses ways to target these stem cells during and before their pluripotent repopulation, and covers potential avenues for further research.

    • 5 min

Top Podcasts In Medicine

More by ecancer